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Abstract
Objective:  To estimate the mortality rate of patients newly diagnosed with chronic atrial
fibrillation (AF) and compare it with the one in the general population. To evaluate the role of co-
morbidity and other factors on the risk of dying among AF patients.
Methods: We used the General Practice Research Database in the UK to perform a retrospective
cohort study. We followed a cohort of chronic AF patiens (N = 1,035) and an age and sex matched
cohort of 5,000 subjects sampled from the general population. We used all deceased AF patients
as cases (n = 234) and the remaining AF patients as controls to perform a nested case-control
analysis. We estimated mortality risk associated with AF using Cox regression. We computed
mortality relative risks using logistic regression among AF patients.
Results: During a mean follow-up of two years, 393 patients died in the general population cohort
and 234 in the AF cohort. Adjusted relative risk of death in the cohort of AF was 2.5 (95%CI 2.1 –
3.0) compared to the general population. Among AF patients, mortality risk increased remarkably
with advancing age. Smokers carried a relative risk of dying close to threefold. Ischaemic heart
disease was the strongest clinical predictor of mortality with a RR of 3.0 (95% CI; 2.1–4.1). Current
use of calcium channel blockers, warfarin and aspirin was associated with a decreased risk of
mortality.
Conclusions: Chronic AF is an important determinant of increased mortality. Major risk factors
for mortality in the AF cohort were age, smoking and cardiovascular co-morbidity, in particular
ischaemic heart disease.
Background
Atrial fibrillation (AF) is a common cardiovascular disease
among adults associated with a substantial morbidity and
increased mortality [1–3]. Incidence of AF increases mark-
edly with advancing age [4,5], with an incidence rate of
less than 0.1 per 1,000 person years among subjects aged
40 to 49, rising to 8.6 among subjects aged 80–89 years. It
has been recognised that AF is an important risk factor for
all-cause mortality, mainly due to an increased risk of car-
diovascular deaths [6,7].
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Results from different studies report that patients with AF
have a mortality rate about twice that of age- and sex-
matched individuals without AF [8,9]. In the Framingham
Heart study, the excess mortality associated with AF per-
sisted after adjustment for the preexisting cardiovascular
conditions [2]. Aging, diabetes, heart failure and myocar-
dial infarction were found to be independent risk factors
for cardiovascular mortality among patients with chronic
AF [2,10]. However, the information on the impact of
chronic AF on mortality in the general population is lim-
ited, and to the best of our knowledge no study with UK
data has been published.
We therefore conducted a study on the mortality rate in a
population-based cohort of patients newly diagnosed
with permanent/chronic atrial fibrillation and compared
it with the one in a general population cohort. We evalu-
ated the role of co-morbidity, drug treatments and other
factors on the risk of dying among AF patients.
Materials and Methods
We used the General Practice Research Database (GPRD)
in the UK to perform a population based cohort study.
The GPRD contains prospectively collected medical infor-
mation on about 3 million patients. This database has
been used in multiple epidemiologic studies that have
confirmed the completeness and validity of the recorded
data [11–13]. We identified a total of 703,730 patients in
the GPRD meeting the following conditions: 40–89 years
old enrolled with a general practitioner for more than two
years and a computerized prescription history of at least
one year before January 1996. This was done to ensure
that the patients have had at least one contact with the GP
in the year prior to entering the study. Patients with a code
for cancer (I CD 1400–2099) before January 1996 were
omitted. From this source population we identified both
study cohorts.
Study cohorts
AF cohort: We identified patients aged 40–89 years with a
first ever recorded diagnosis of permanent/chronic atrial
fibrillation in 1996. The diagnosis was confirmed by the
general practitioners (GPs) through a questionnaire, this
process is describe in detailed in a previous study [4]. We
requested the GPs to confirm whether the episode of
chronic AF was the first ever and to provide information
on diagnostic tests, procedures and aetiology of the AF
(patient confidentiality was always preserved). We exclud-
ed patients classified by the GP as having paroxysmal AF,
1,035 were finally confirmed. General Population cohort:
Using the same source population in which the AF pa-
tients were identified and applying the same eligibility cri-
teria as for the AF cohort, we sampled an age and sex
matched cohort of 5,000 individuals free of AF.
Analysis
The two cohorts were followed up from date of first diag-
nosis of chronic AF (start date) and from a random date
during 1996 in the general population cohort until the
earliest of death, or end of follow-up (December 1999).
Survival probability was computed in both cohorts and
we estimated the relative risk of dying associated with AF
using Cox proportional hazard regression to control for
risk factors.
A nested case-control analysis was performed in the AF co-
hort to assess risk factors of death. We used all deceased
AF patients as cases (n = 234) and used their death date as
index date. The remaining alive AF patients (n = 801) were
considered controls and we sampled a random date dur-
ing their follow-up period that was used as their index
date. Estimates of mortality risk and 95% confidence in-
terval (CI) were computed using logistic regression. We
collected recorded information on the following risk fac-
tors: smoking status, BMI, alcohol consumption, as well
as prior history of heart failure (HF), ischaemic heart dis-
ease (IHD), cerebrovascular disease (CVD), hypertension
and diabetes. We used both the information in the ques-
tionnaire and computerized files to ascertain the cause of
death.
Drug exposure definition
We extracted from computerized records information on
drugs used to treat AF between start date and index date:
diuretics, beta-blockers, ACE inhibitors, calcium channel
blockers, digoxin, aspirin, warfarin, NSAIDs, and other
anti-arrhythmic drugs (disopyramide, procainamide, qui-
nidine, flecainide, propafenone and amiodarone). We de-
fined current use when drug supply lasted until index date
or ended in the previous month. We considered short-
term use when duration was less than 3 months, and long-
term use when duration was more than 3 months. Past
use was considered when the end of the most recent pre-
scription was more than one month before index date and
non use when there was no drug use between start and in-
dex date.
Results
During a mean follow-up of close to two years, 393 pa-
tients died in the general population cohort and 234 in
the AF cohort. Patients with AF had a significantly lower
survival than patients from the general population with-
out AF (Figure 1). The increased mortality was already
present in the early phase of follow-up. Half of the deaths
in the AF cohort were related to ischaemic heart disease
(IHD) or other cardiovascular diseases (45% of all cause
mortality). In the general population cohort, these two
causes accounted for 29% of all deaths (table 1). The rel-
ative risk of mortality among patients with chronic atrial
fibrillation was 2.5 (95% CI 2.1–3.0) compared to theBMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/5
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general population after adjusting for co-morbidity and
major clinical risk factors (table 2). This risk was 2.3 (95%
CI 1.8–3.0) in men and 2.8 (95% CI 2.2–3.6) in women.
When considering only cerebro- and cardio-vascular
deaths (n= 306), the corresponding adjusted RR associat-
ed with chronic AF was 3.7 (95% CI 3.0–4.7).
Table 3 shows the effect of several factors on the mortality
risk in the cohort of chronic AF patients. The mortality risk
increased remarkably with advancing age. Smokers car-
ried a relative risk of dying close to threefold. Diabetes,
heart failure and cerebrovascular disease were all associat-
ed with estimates of RR between 1.5 and 2. Ischaemic
heart disease was the strongest clinical predictor of mor-
tality with a RR of 3.0 (95% CI; 2.1–4.1). We did not find
any significant association between alcohol consumption
and mortality. Overweight patients (BMI of 30 or more)
had a relative risk of 0.5 (95%CI: 0.3–0.9) compared to
subjects with a BMI between 22 and 25 after adjusting for
age, sex, smoking and preexisting conditions.
Figure 1
Kaplan-Meier survival curve for chronic atrial fibrilla-
tion and general population cohorts. (mean follow-up
time 22 months -SD 12.9; range: 0.5–47 months).
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Table 1: Distribution of causes of death in the cohort of chronic atrial fibrillation patients and the general population
General Population Cohort AF Cohort
N = 393 % N = 234 %
Causes of death
Ischaemic heart disease (IHD) 70 17.8 61 21.1
Other cardiovascular no IHD * 42 10.7 56 24
Cerebrovascular disease† 44 11.2 33 14.1
Cancer 64 16.3 27 11.5
Other diseases§ 107 27.2 48 20.5
Unknown 66 16.8 9 3.8
* Includes heart failure, heart valvular and rhythm disorders and vascular diseases (PVD, aneurism, pulmonary embolism). †includes ischaemic and 
haemorrhagic cerebrovascular accidents. §Includes respiratory, gastrointestinal, liver, renal diseases, infection and trauma.
Table 2: Incidence rate and relative risk of death in the cohort of chronic atrial fibrillation patients compared to the general population
General Population Cohort AF Cohort
Person-years 9261 1898
Deaths 393 234
Mortality rate/100 p-years (95% Cl) 4.2 (3.8–4.7) 12.3 (10.8–14.0)
Relative Risk * (95% Cl) 1 2.5 (2.1 – 3.0)
* Relative risk estimated by Cox regression including age, sex, smoking, diabetes, heart failure, 'Ischaemic heart disease, hypertension, cerebrovas-
cular diseaseBMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/5
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Current use of calcium channel blockers, aspirin and war-
farin were associated with a significant reduced risk of all
cause mortality (Table 4). When we separated current use
into short and long term use (less than 3 months of use
versus more), we observed that the reduced risk of mortal-
ity was mainly among long-term users of these drugs. Us-
ers of calcium channel blockers for more than 3 months
carried a risk of 0.4 (95%CI 0.2–0.7), the respective esti-
mates for warfarin long term users was 0.4 (95%CI 0.3–
0.8) and for aspirin (RR: 0.6; 95%CI 0.4–0.9). Current use
of NSAIDs was associated with an increased mortality (RR
of 1.8; 95% CI 1.0–3.2).
The estimates of mortality risk for all risk factors evaluated
only changed marginally when we restricted the analysis
to cardiovascular deaths that included IHD, heart failure,
other cardiovascular and cerebrovascular diseases (data
not shown).
Discussion
We found that permanent AF is an important independ-
ent predictor of mortality. AF patients carried an all cause
mortality risk close to 3 times greater than the one in an
age and sex matched general population cohort. We are
not aware of other studies that have evaluated the impact
of chronic AF on mortality in a UK general population set-
ting.
Some specific characteristics of the study need to be con-
sidered. Firstly, the ascertainment of AF in general popu-
lation is problematic, as some of the cases can remain
undetected if these episodes are brief mild [5]. We only
studied chronic AF and by using a general practice setting
we tried to ensure that even less severe cases of AF could
be identified. There is always room for missclassification
between paroxysmal and chronic AF. We tried to mini-
mise this potential bias by reviewing all computerized his-
tories of AF patients and finally requesting the GP to
confirm the diagnosis of chronic AF. The higher probabil-
ity of detecting more severe or symptomatic cases -those
that contact the GP- may lead to a slight overestimation of
mortality associated with AF, and could explain the higher
mortality rate found in our study compared to studies us-
ing screening methods for case ascertainment. Secondly,
we could not ascertain the underlying cause of death in
12% of the subjects and this proportion was higher
Table 3: Risk of mortality associated with different risk factors among chronic atrial fibillation patients.
Cases Controls Odds Ratio*
n = 234 (%) n = 801 (%) (95% CI)
Sex
Males 115 (49.1) 372 (53.6) 1
Females 119 (50.9) 429 (46.4) 0.9 (0.6–1.3)
Age
40–59 years 4 (1.7) 67 (8.4) 1
60–69 years 19 (8.1) 136 (17.0) 1.9 (0.6–5.9)
70–79 years 93 (39.7) 325 (40.6) 4.0 (1.4 – 11.7)
80–89 years 118 (50.4) 273 (34.1) 6.0 (2.0–17.6)
Smoking status
Never smoker 108 (46.2) 486 (60.7) 1
Smoker 59 (25.2) 127 (15.9) 2.6 (1.7–4.0)
Ex-smoker 28 (12.0) 84 (10.5) 1.6 (0.9–2.7)
Unknown 39 (16.7) 104 (13.0) 1.7 (1.0–2.9)
BMI (weight /height2)
<22 30 (12.8) 82 (10.2) 1.0 (0.6–1.9)
22–24.9 49 (20.9) 138 (17.2) 1
25–30 60 (25.6) 227 (28.3) 0.8 (0.5–1.3)
+30 20 (8.5) 131 (16.4) 0.5 (0.3–0.9)
Unknown 75 (32.1) 223 (27.8) 0.9 (0.5–1.5)
Prior co-morbidity
Diabetes 30 (12.8) 59 (7.4) 2.1 (1.3–3.6)
Heart Failure 137 (58.5) 271 (33.8) 1.9 (1.4–2.7)
Ischemic heart disease 127 (54.3) 206 (25.7) 3.0 (2.1 – 4.2)
Hypertension 104 (44.4) 355 (44.3) 0.9 (0.7–1.3)
Cerebrovascular disease 73 (31.2) 159 (19.9) 1.5 (1.1 – 2.2)
*Estimates of risk are adjusted for all variables included in the table using logistic regression.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/5
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among the general population cohort than in than AF pa-
tients cohort. Atrial fibrillation patients have a higher con-
sultation rate with their GP than the general population
and as a result these patients tend to have more informa-
tion recorded on minor morbidity and causes of death
than patients from the general population. Third, we had
a considerable level of missing information on BMI,
mainly due to unrecorded data on height not routinely
measured in elderly and other risk factors.
Estimates of mortality risk associated with AF have been
reported to be around two for all cause mortality, and be-
tween two and twelve for cardiovascular mortality [14].
Our corresponding estimate for the latter end-point was
close to four while our findings of all cause mortality risk
associated with chronic AF were in the higher range of
those from previous studies. The small difference can part-
ly be explained by the different methods used in the iden-
tification of AF patients, the inclusion of different types of
AF (chronic versus all AF) and the distinct ascertainment
of causes of death [2,3,9,14]. Among patients with at least
one other cardiovascular diagnosis, mortality risk was ap-
proximately 20% higher in patients with AF compared to
those without AF [9]. In the Framingham Heart Study, the
authors reported that the excess mortality attributed to
atrial fibrillation (chronic, paroxysmal or flutter) was in-
dependent of preexisting cardiovascular conditions asso-
ciated with atrial fibrillation. Their estimate of mortality
Table 4: Risk of mortality associated with use of cardiovascular treatment drugs in the AF cohort
Cases Controls Odds Ratio*
n = 234 (%) n = 801 (%) (95% CI)
Diuretics
Non use 46 (19.7) 237 (29.6) 1
Current use 135 (57.7) 419 (52.3) 1.1 (0.6–1.7)
Past use 53 (22.6) 145 (18.1) 1.1 (0.6–1.9)
Beta Blockers
Non use 169 (72.2) 561 (70.0) 1
Current use 13 (5.6) 87 (10.9) 0.8 (0.4–1.6)
Past use 52 (22.2) 153 (19.1) 1.0 (0.6–1.6)
ACE inhibitors
Non use 137 (58.5) 524 (65.4) 1
Current use 70 (29.9) 208 (26.0) 0.8 (0.5–1.3)
Past use 27 (11.5) 69 (8.6) 1.0 (0.5–1.8)
Calcium Channel
Blockers
Non use 165 (70.5) 560 (69.9) 1
Current 18 (7.7) 125 (15.6) 0.4 (0.2–0.7)
Past use 51 (21.8) 116 (14.5) 1.2 (0.7–1.8)
Digoxin
Non use 51 (21.8) 191 (23.8) 1
Current 143 (61.1) 496 (61.9) 0.9 (0.6–1.4)
Past use 40 (17.1) 114 (14.2) 1.0 (0.5–1.7)
Amiodarone †
Non use 212 (90.6) 726 (90.6) 1
Current 14 (6.0) 44 (5.5) 1.3 (0.6–2.8)
Past use 8 (3.4) 31 (3.9) 0.8 (0.3–2.2)
Warfarin
Non use 174 (74.4) 503 (62.8) 1
Current 37 (15.8) 226 (28.2) 0.5 (0.3–0.8)
Past use 23 (9.8) 72 (9.0) 1.0 (0.5–1.8)
Aspirin
Non use 109 (46.6) 407 (50.8) 1
Current 72 (30.8) 239 (29.8) 0.6 (0.4–0.9)
Past use 53 (22.6) 155 (19.4) 0.8 (0.5–1.2)
*Estimates are adjusted for age, sex, smoking, diabetes, heart failure, 'Ischaemic heart disease, hypertension, cerebrovascular disease and all the 
drugs groups in the table, using logistic regression. †There was no use of other antiarrhythmic drugs (disopyramide, procainamide, quinidine, flecai-
nide and propafenone).BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/5
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associated with atrial fibrillation was 1.5 in men and 1.9
in women after adjusting for other cardiovascular co-mor-
bidity [2]. In our study we only assessed the risk among
chronic AF patients, and found higher estimates of risk for
both men (RR = 2.3) and women (RR = 2.8) after taking
into account preexisting diseases commonly associated
with AF, such as IHD or HF. It could be argued that chron-
ic forms of AF carry a greater mortality risk than paroxys-
mal AF and flutter, and this could explain the higher
estimates observed in our study.
In agreement with previous studies, we confirmed that the
major risk factors for mortality in AF patients are old age,
smoking and cardiovascular co-morbidity [2,10,14]. We
identified the same risk factors and with a similar magni-
tude of risk when restricting the outcome to specific cardi-
ovascular mortality. Another study found that the
increased risk for all cause mortality in AF patients was
largely due to an increased mortality risk due to ventricu-
lar failure [7]. In our study, we observed that half of all
deaths were due to IHD and other cardiovascular diseases
in the AF cohort. A previous review by Alpert et al [15] re-
ported that the mortality risk was age dependent and pres-
ence of HF at the time of onset of AF was an important
prognostic factor. In our study, we found that coexisting
heart failure carried a two fold increased risk of all cause
mortality and ischaemic heart disease a three fold in-
crease.
The use of anti-arrhythmic drugs and digoxin for atrial fi-
brillation among patients with coexisting cardiovascular
morbidity has been controversial [16–18]. An increased
risk of cardiac mortality has been reported among AF pa-
tients with a history of congestive heart failure receiving
anti-arrhythmic drugs compared to patients not treated
[16,19]. Other studies have concluded that anti-arrhyth-
mic drug therapy in AF patients does not translate into an
improvement in mortality and have suggested that class I
anti-arrhythmic drugs should be avoided in AF patients
with advanced heart failure [20]. We found no significant
difference in mortality risk among those treated and not
treated with anti-arrhythmic drugs such as amiodarone,
beta blockers or digoxin after adjusting for cardiovascular
disease and other drug treatment. Though we found some
evidence for a protective effect with some drug treatments,
one should be cautious in interpreting these results due to
the observational design of our study and the relative sta-
tistical variability.
In our study, obesity (BMI>30) was associated with a 50
% reduced risk of all cause mortality. The Longitudinal
Study of Aging reported a reduced mortality in obese eld-
erly people after adjustment for other factors [21]. We
could not find any published study that examined this as-
sociation among AF patients and further studies are war-
ranted to confirm this finding.
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